SLC2A1 and cancer: In recent years, GLUT1 has gradually become a research hotspot in the field of metabolic diseases, cancer, and other diseases, and is considered as an important target for drug development (Xiao et al., 2018; Li et al., 2019; Bertrand et al., 2020).